Cardiac remodeling and arrhythmogenesis are ameliorated by administration of Cx43 mimetic peptide Gap27 in heart failure rats

Sci Rep. 2020 Apr 23;10(1):6878. doi: 10.1038/s41598-020-63336-6.

Abstract

Alterations in connexins and specifically in 43 isoform (Cx43) in the heart have been associated with a high incidence of arrhythmogenesis and sudden death in several cardiac diseases. We propose to determine salutary effect of Cx43 mimetic peptide Gap27 in the progression of heart failure. High-output heart failure was induced by volume overload using the arterio-venous fistula model (AV-Shunt) in adult male rats. Four weeks after AV-Shunt surgery, the Cx43 mimetic peptide Gap27 or scrambled peptide, were administered via osmotic minipumps (AV-ShuntGap27 or AV-ShuntScr) for 4 weeks. Cardiac volumes, arrhythmias, function and remodeling were determined at 8 weeks after AV-Shunt surgeries. At 8th week, AV-ShuntGap27 showed a marked decrease in the progression of cardiac deterioration and showed a significant improvement in cardiac functions measured by intraventricular pressure-volume loops. Furthermore, AV-ShuntGap27 showed less cardiac arrhythmogenesis and cardiac hypertrophy index compared to AV-ShuntScr. Gap27 treatment results in no change Cx43 expression in the heart of AV-Shunt rats. Our results strongly suggest that Cx43 play a pivotal role in the progression of cardiac dysfunction and arrhythmogenesis in high-output heart failure; furthermore, support the use of Cx43 mimetic peptide Gap27 as an effective therapeutic tool to reduce the progression of cardiac dysfunction in high-output heart failure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Arrhythmias, Cardiac / complications
  • Arrhythmias, Cardiac / diagnostic imaging
  • Arrhythmias, Cardiac / drug therapy*
  • Arrhythmias, Cardiac / physiopathology*
  • Arteriovenous Shunt, Surgical
  • Cardiomegaly / complications
  • Cardiomegaly / diagnostic imaging
  • Cardiomegaly / physiopathology
  • Connexin 43 / chemistry*
  • Connexins / administration & dosage
  • Connexins / therapeutic use*
  • Fibrosis
  • Heart Failure / complications
  • Heart Failure / diagnostic imaging
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology*
  • Heart Ventricles / drug effects
  • Hemodynamics / drug effects
  • Male
  • Oligopeptides / administration & dosage
  • Oligopeptides / therapeutic use*
  • Peptides / administration & dosage
  • Peptides / therapeutic use*
  • Rats, Sprague-Dawley
  • Vasodilation / drug effects
  • Ventricular Remodeling / drug effects*

Substances

  • Connexin 43
  • Connexins
  • Oligopeptides
  • Peptides
  • gap 27 peptide